Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from IO Biotech ( (IOBT) ) is now available.
On February 12, 2026, IO Biotech received a notice from Nasdaq that it had fallen out of compliance with the Nasdaq Global Select Market’s continued listing standards because its market value of listed securities had been below the required $50 million minimum for 30 consecutive business days. The notice does not immediately affect trading of the company’s common stock, but IO Biotech has until August 11, 2026, to restore its market value to at least $50 million for a minimum of ten consecutive business days or risk potential delisting, a development that could impact investor confidence and the company’s access to capital markets.
Nasdaq may require IO Biotech to demonstrate compliance for a longer period and, if the company fails to regain compliance by the deadline, could move to delist the stock, though IO Biotech would have the option to appeal any such determination under Nasdaq procedures. The company cautioned that there is no assurance it will regain compliance with the market value requirement or meet other Nasdaq listing rules, underscoring uncertainty for shareholders and other stakeholders regarding the company’s future listing status.
The most recent analyst rating on (IOBT) stock is a Hold with a $0.30 price target. To see the full list of analyst forecasts on IO Biotech stock, see the IOBT Stock Forecast page.
Spark’s Take on IOBT Stock
According to Spark, TipRanks’ AI Analyst, IOBT is a Neutral.
The score is primarily driven lower by weak financial performance (pre-revenue, large losses, substantial cash burn, and sharply thinner equity cushion) and bearish technicals (price below all major moving averages with negative MACD). Corporate events further increase downside and financing/listing risk, while valuation metrics provide limited offset due to negative earnings and no dividend.
To see Spark’s full report on IOBT stock, click here.
More about IO Biotech
IO Biotech, Inc. operates in the biotechnology sector and is listed on the Nasdaq Global Select Market. The company’s common stock is publicly traded, and its valuation is subject to Nasdaq’s market value listing standards, including a minimum market value of listed securities threshold of $50 million.
Average Trading Volume: 9,954,961
Technical Sentiment Signal: Sell
Current Market Cap: $25.58M
See more insights into IOBT stock on TipRanks’ Stock Analysis page.